How to Cite:
Resheed, W. A. (2022). Drug timing in glaucoma. *International Journal of Health Sciences*, *6*(S1), 11575–11577. https://doi.org/10.53730/ijhs.v6nS1.7812

Drug timing in glaucoma

Dr. Wesen Abdulaziz Resheed

***Abstract*---**Most ptaient going through distribution Of their drug over day and night baours with lorg interwal of few hours without adding new treatment get benefit from trail by improving their symptoms of eyea chpain and by about 1 line avarge imporving of there vision and their life quality. Widseparation interval by about 4 hours between different antiglucoma drug is benificial to control Iop flactuationg.

***Keywords*---**Drug timing, glaucoma, antiglucoma.

Introduction

-Glaucoma
Is a specific optic neuropathy that related to visual field changes with or with out increased intra ocular pressure (lop)
-many factor play rules in management of glucoma include medical , surgical and environmental .factors each of which has its significance and impact on patient health
It is now a day one of major causes of Blindness in world because of its prevalence , its silence and it's cost –related hitchs nowadays , the normal tension glaucoma has scary rate of increase among young people which related to complex life style and prolong aneixty , the height suspicion index is needed for early diagnosis of the disease screen of I.O.P not only for 40s people , but even younger than 40s for eyeach or blurre of recurrent pattern, even without these , optic disc view is mandatory for each eye-department patient even with simple complain , this help to discover many silent cases early and prevent further optic fiber damage.

Method

-The study include 20 patients whome diagnosed by glucoma and on their medical treatment years ago and their medication include dual or triple theropy . all patient use their medication all together with 10 min apart between drug as adviced , all these patients have in there followup heigh Iop pain and VF progression.
Befor try to add new drug for duul therapy or send paticnt to surgery whose already on Triple therapy , atrail of redistribution of their agent along the day hours to ensur more IOP control and less Diurnal flactuation

-It was to add afternoon dose and early evening dose in addtion to early morning and night doses , and (at bed) dose
With 4 to 6 hoursinterval between these doses with out adding systemic agent nor anew topical one.

Data

age	Sex	Later-ality	Pain?	CID ratio	Iop (mmHg)	Iop Post	V A post treatment	VA pretreatment
70 y	♀	ou	Yes	0.8 × 0.7	25 × 18	14 × 14	6.36 × HM	H.m ou
65	♀	ou	No	0.5 × 0.9	17 × 22	13× 14	6.24 × c.f2m	6.36× c.f 1m
68	♀	ou	Rt	0.5 ×0.7	26 × 20	11× 12	6.18 pou	6.36 ou
19	♀	Lt	Lt	0.6	20	16	6.9 with glasses	6.12 pwith glasses
45	♀	It	It	0.5	23	14	6.9	6.18
50	♀	It	It	0.5	18	12	6.12	6.12 p
17	♀	It	It	0.4	22	13	6.6	6.9_p
67	♀	It	It	0.9	23	14	C.f 3m	c.f 1 m
45	♀	Rt	Rt	0.7	30	15	6.36	c.f 6 m
55	♀	Ou	No	0.4 ×0.6	19 × 20	13× 13	6.9 ou	6.9_p × 6.12
60	♀	It	It	0.6	20	12	6.12	6.18 p
57	♀	Ou	Ou	Total × 0.7	30 × 25	16× 15	6.18p	Tt:6.36
49	♀	It	It	0.4	23	15	6.6	6.9P

Data

age	Sex	Later-ality	Pain?	CID ratio	Iop (mmHg)	Iop Post	VA post	VA pre
13	♀	ou	It	0.5	19	12	6.18	6.36
69	♀	Lt	It	0.5	21	14	6.6	6.69
41	♀	It	NO	0.4	22	12	6.6	6.9p
25	♀	ou	NO	09×09	26×27	13×13	HM	LP × Lp
37	♀	Rt	Rt	0.6	23	14	6.9p	6.12p
53	♀	Rt	NO	0.7	22	12	6.9 p	6.18
46	♀	ou	NO	0.6×0.9	22×22	13×12	6.18p	6.24
							×6.60	×6.60

Result

Most ptaient going through distribution Of their drug over day and night baours with lorg interwal of few hours without adding new treatment get benefit from trail by improving their symptoms of eyea chpain and by about 1 line avarge imporving of there vision and their life quality , somes back depend them self again in their daily requirment of path feeding even visual field show some changes reflect the improvement in the function of morbid /sick gonglion cells after Iop declin present as decrease in stimuli intensity needs and disappearance of some early burden points from the field

Conclusion

Widseparation interval by about 4 hours between different antiglucoma drug is benificial to control Iop flactuationg, visual acuity –Visual Field progressions, improv patient is life quality and Compail.

Reference

Shaarawy, T., & Grehn, F. (Eds.). (2009). *Guidelines on design and reporting of glaucoma surgical trials*. Kugler publications.

Crowston, J. G., Akbar, A. N., Constable, P. H., Occleston, N. L., Daniels, J. T., & Khaw, P. T. (1998). Antimetabolite-induced apoptosis in Tenon's capsule fibroblasts. Investigative ophthalmology & visual science, 39(2), 449-454.

Sherwood, M. B., Grierson, I., Milgar, L., & Hitchings, R. A. (1989). Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. *Ophthalmology*, *96*(3), 327-335. https://doi.org/10.1016/S0161-6420(89)32888-0

Hitchings, R. (2012). People can talk about their practices. *Area*, *44*(1), 61-67.